Publication
Abstract
A phase 3, randomized, open-label study investigating the efficacy of the BITE antibody blinatumomab versus standard of care chemotherapy in adults subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) (TOWER study)